Nifty 16912.25 (-1.65%)
Sensex 56747.14 (-1.65%)
Nifty Bank 35735.9 (-1.27%)
Nifty IT 34879.4 (-2.70%)
Nifty Financial Services 17596.7 (-1.03%)
Adani Ports 723.45 (-1.90%)
Asian Paints 3038.30 (-2.32%)
Axis Bank 663.10 (-1.47%)
B P C L 383.45 (-0.63%)
Bajaj Auto 3249.75 (-1.16%)
Bajaj Finance 6951.75 (-1.66%)
Bajaj Finserv 16893.45 (-3.40%)
Bharti Airtel 697.60 (-2.89%)
Britannia Inds. 3496.20 (-1.62%)
Cipla 894.95 (-1.87%)
Coal India 148.55 (-7.01%)
Divis Lab. 4646.80 (-2.32%)
Dr Reddys Labs 4498.70 (-2.13%)
Eicher Motors 2444.10 (-0.47%)
Grasim Inds 1660.75 (-2.53%)
H D F C 2768.80 (-0.10%)
HCL Technologies 1136.55 (-2.98%)
HDFC Bank 1503.80 (-0.64%)
HDFC Life Insur. 684.20 (-0.98%)
Hero Motocorp 2420.00 (-1.72%)
Hind. Unilever 2306.50 (-1.59%)
Hindalco Inds. 421.35 (-0.78%)
I O C L 120.95 (-1.02%)
ICICI Bank 709.55 (-0.94%)
IndusInd Bank 915.65 (-3.73%)
Infosys 1695.30 (-2.32%)
ITC 217.90 (-1.69%)
JSW Steel 642.85 (-0.26%)
Kotak Mah. Bank 1885.20 (-1.51%)
Larsen & Toubro 1782.65 (-1.03%)
M & M 822.15 (-1.77%)
Maruti Suzuki 7042.85 (-2.30%)
Nestle India 19016.50 (-1.58%)
NTPC 124.35 (-2.09%)
O N G C 143.35 (-1.75%)
Power Grid Corpn 202.00 (-1.99%)
Reliance Industr 2362.60 (-1.90%)
SBI Life Insuran 1148.50 (-1.50%)
Shree Cement 25612.35 (-1.16%)
St Bk of India 465.30 (-1.66%)
Sun Pharma.Inds. 737.15 (-1.95%)
Tata Consumer 747.60 (-3.45%)
Tata Motors 467.20 (-2.69%)
Tata Steel 1108.80 (-0.82%)
TCS 3536.40 (-2.86%)
Tech Mahindra 1551.75 (-2.61%)
Titan Company 2325.30 (-1.86%)
UltraTech Cem. 7214.60 (-1.61%)
UPL 716.55 (0.53%)
Wipro 624.50 (-2.54%)
ZYDUSWELL

Zydus Wellness Ltd.

₹1929.3
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

  • Master Rating:
  • Zydus Wellness has an operating revenue of Rs. 1,968.54 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 6% is okay, ROE of 2% is fair but needs improvement. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 13 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 128 indicates it belongs to a poor industry group of Food-Misc Preparation and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

As per analysts rating in the last 6 months, the recommendation isHOLD Zydus Wellness

Zydus Wellness Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Zydus Wellness Ltd Synopsis

NSE-Food-Misc Preparation

Zydus Wellness Ltd. belongs to the Industry of Personal Care. Company’s Total Operating Revenue is Rs. 113.83 Cr. and Equity Capital is Rs. 63.63 Cr. for the Year ended 31/03/2021. Zydus Wellness Ltd. is a Public Limited Listed company incorporated on 01/11/1994 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L15201GJ1994PLC023490 and registration number is 023490.
  • Market Cap

    INR 12,249.16 Cr

  • Sales

    INR 164.84 Cr

  • Shares in Float

    2.23 Cr

  • No of Funds

    96 K

  • Yield

    0.26%

  • Book Value

    3.03

  • U/D Vol Ratio

    0.7

  • LTDebt/Equity

    47%

  • Alpha

    0

  • Beta

    0.19

Zydus Wellness Ltd Ownership
Zydus Wellness Ltd Management

Zydus Wellness Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 4019.293214.73325.24691.19557.19
Fixed Assets Annual Cr 44.9244.1938.3738.6440.4
Total Non Current Assets Annual Cr 3984.214715.124855.6945.2749.6
Total Current Assets Annual Cr 132.2487.6498.47693.89555.13
Total Assets Annual Cr 4116.454802.764954.16739.16604.73
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 631.665557.526576.697176.91142.613
ROE Annual % -4.53-1.262.8919.3519.62
ROCE Annual % 0.331.812.6919.619.56
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 1557.7552.1652.750.16

Zydus Wellness Ltd Technicals

EMA & SMA

CURRENT PRICE

1929.3 (0.75)

    • Bullish Moving Averages 0
    • Bearish Moving Averages 16

EMA

  • 20 Day

    2006.74

  • 50 Day

    2098.81

  • 100 Day

    2138.56

  • 200 Day

    2118.28

Zydus Wellness Ltd Resistance and support

1925.22 PIVOT

  • First Resistance

    1943.59

  • Second Resistance

    1972.17

  • Third Resistance

    1990.54

  • First Support

    1896.64

  • Second Support

    1878.27

  • Third Support

    1849.69

  • RSI

    29.13

  • MFI

    41.25

  • MACD

    -55.06

  • MACD signal line

    -54.23

Zydus Wellness Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 30,867 1,296,723 42.01%
Week 19,416 1,084,988 55.88%
1 Month 20,649 1,161,489 56.25%
6 Month 45,118 2,536,561 56.22%

Zydus Wellness Ltd Price change analysis

-123

Over 1 month

Low High
1898 2099

-355

Over 3 month

Low High
1898 2476.85

-167.6

Over 6 months

Low High
1898 2476.85

102.05

Over Year

Low High
1808 2476.85

Similar Stocks

News

Companies gear up for Omicron version of coronavirus vaccine

Zydus to keep a laboratory product ready based on the new variant Read More

ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulati

Intimation of Newspaper Publication of loss of share Certificate. Read More

ZYDUS WELLNESS LTD.-$ - 531335 - Intimation Of Related Party

Intimation Of Related Party Transaction On Consolidated Basis For The Half Year Ended On September 30, 2021. Read More

ZYDUS WELLNESS LTD.-$ - 531335 - Intimation Of Related Party

Intimation of Related Party Transaction on Consolidated basis for the half year ended on September 30, 2021. Read More

Zydus gets USFDA nod to market Decitabine injection in the U

Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer Read More

Blogs

FAQs

Stock Directory-

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All 0-9